← Back to Search

Device

Tumor Treatment Fields for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By John Waters, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Diagnosis of stage I-IIIA NSCLC planned for surgical resection.
2. Eastern Cooperative Oncology Group (ECOG) 0-2 performance status.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 14-28 days
Awards & highlights

Summary

The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC). TTField is a non-invasive treatment that uses low-intensity electrical fields to treat cancer. Resection is the medical term for surgically removing part or all of a tissue, structure, or organ.

Who is the study for?
This trial is for individuals with early-stage (I-IIIA) Non-Small Cell Lung Cancer who are candidates for surgery to remove the cancer. Participants should be able to undergo the TTFields treatment before their surgery.
What is being tested?
The study is testing the NovoTTF-200T System, a non-invasive device that delivers low-intensity electrical fields (TTFields) aimed at treating lung cancer by disrupting cancer cell division.
What are the potential side effects?
Potential side effects of using the NovoTTF-200T System may include skin irritation beneath the device pads, headaches, and malaise. However, since it's non-invasive, it tends to have fewer side effects than more aggressive treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 14-28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 14-28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.
Secondary study objectives
Safety of administering TTFields

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tumor Treatment FieldsExperimental Treatment1 Intervention
Duration: 2-4 week; target 18 hours/day (on average). Continuous between time of enrollment and date of surgery. Cycle Length: 2-4 weeks

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,064 Previous Clinical Trials
1,055,505 Total Patients Enrolled
NovoCure Ltd.Industry Sponsor
58 Previous Clinical Trials
4,724 Total Patients Enrolled
John Waters, MDPrincipal InvestigatorUT Southwestern Medical Center
~12 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top